Nasdaq · Common stock
Korsana Biosciences (KRSA)
$32.09 +$0.78 (+2.49%)
- Day’s range
- $30.71–$32.42
- Volume
- 230,499
KRSA price history
KRSA closed at $32.09 on Oct. 26, 2026. Over the past year, its daily close ranged from $24.56 on Sept. 10, 2026 to $37.19 on Sept. 24, 2026.
Data table: KRSA daily closes, the past year
| Date | Close |
|---|---|
| Oct. 26, 2026 | $32.09 |
| Oct. 23, 2026 | $31.31 |
| Oct. 22, 2026 | $33.43 |
| Oct. 21, 2026 | $32.54 |
| Oct. 20, 2026 | $31.03 |
| Oct. 19, 2026 | $31.41 |
| Oct. 16, 2026 | $32.38 |
| Oct. 15, 2026 | $33.65 |
| Oct. 14, 2026 | $34.32 |
| Oct. 13, 2026 | $31.66 |
| Oct. 12, 2026 | $34.04 |
| Oct. 9, 2026 | $33.92 |
| Oct. 8, 2026 | $33.51 |
| Oct. 7, 2026 | $31.65 |
| Oct. 6, 2026 | $31.77 |
| Oct. 5, 2026 | $30.72 |
| Oct. 2, 2026 | $30.49 |
| Oct. 1, 2026 | $31.20 |
| Sept. 30, 2026 | $32.00 |
| Sept. 29, 2026 | $34.00 |
| Sept. 28, 2026 | $30.83 |
| Sept. 25, 2026 | $31.00 |
| Sept. 24, 2026 | $37.19 |
| Sept. 23, 2026 | $32.30 |
| Sept. 22, 2026 | $34.98 |
| Sept. 21, 2026 | $33.21 |
| Sept. 18, 2026 | $34.99 |
| Sept. 17, 2026 | $33.72 |
| Sept. 16, 2026 | $31.23 |
| Sept. 15, 2026 | $32.08 |
| Sept. 14, 2026 | $31.61 |
| Sept. 11, 2026 | $31.91 |
| Sept. 10, 2026 | $24.56 |
| Sept. 9, 2026 | $26.20 |
Key figures
- Average daily volume
- 111,415Past 3 months
- Market value
- $1.46B
- Dividend yield
- —
Price change
- 1 month
- +3.52%
What Wall Street says about KRSA
In the past 90 days, Wall Street firms published 5 rating or price-target actions on KRSA: 5 new ratings.
| Action | Rating | |||
|---|---|---|---|---|
| Wedbush | Initiates coverage | Outperform | $44 | |
| Guggenheim | Initiates coverage | Buy | $70 | |
| Stifel | Initiates coverage | Buy | $43 | |
| TD Cowen | Initiates coverage | Buy | — | |
| UBS | Initiates coverage | Buy | $55 |
Ratings and price targets are the firms’ own opinions, reported as published.
Not investment advice.
About Korsana Biosciences, Inc. Common Stock
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.
- Headquarters
- Cambridge, Mass.
- Listed
- Sept. 9, 2026
- Sector
- Health care
- Industry
- Pharmaceutical preparations
In WallStreetDigest editions
No WallStreetDigest article about KRSA is on the site yet.